CalciMedica (CALC) Competitors $3.17 -0.26 (-7.58%) Closing price 09/12/2025 03:59 PM EasternExtended Trading$3.22 +0.06 (+1.74%) As of 09/12/2025 06:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CALC vs. IPHA, NLTX, BDTX, BIOA, FTLF, CGTX, MDWD, TIL, TVGN, and SXTCShould you be buying CalciMedica stock or one of its competitors? The main competitors of CalciMedica include Innate Pharma (IPHA), Neoleukin Therapeutics (NLTX), Black Diamond Therapeutics (BDTX), BioAge Labs (BIOA), FitLife Brands (FTLF), Cognition Therapeutics (CGTX), MediWound (MDWD), Instil Bio (TIL), Tevogen Bio (TVGN), and China SXT Pharmaceuticals (SXTC). These companies are all part of the "pharmaceutical products" industry. CalciMedica vs. Its Competitors Innate Pharma Neoleukin Therapeutics Black Diamond Therapeutics BioAge Labs FitLife Brands Cognition Therapeutics MediWound Instil Bio Tevogen Bio China SXT Pharmaceuticals CalciMedica (NASDAQ:CALC) and Innate Pharma (NASDAQ:IPHA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, earnings, profitability, dividends, analyst recommendations, valuation, media sentiment and institutional ownership. Which has better valuation and earnings, CALC or IPHA? CalciMedica has higher earnings, but lower revenue than Innate Pharma. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCalciMedicaN/AN/A-$13.70M-$1.60-1.98Innate Pharma$12.62M14.61-$53.53MN/AN/A Do insiders & institutionals have more ownership in CALC or IPHA? 0.2% of Innate Pharma shares are owned by institutional investors. 41.5% of CalciMedica shares are owned by company insiders. Comparatively, 31.9% of Innate Pharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Do analysts prefer CALC or IPHA? CalciMedica currently has a consensus price target of $16.00, indicating a potential upside of 404.73%. Innate Pharma has a consensus price target of $11.00, indicating a potential upside of 450.00%. Given Innate Pharma's stronger consensus rating and higher possible upside, analysts clearly believe Innate Pharma is more favorable than CalciMedica.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CalciMedica 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Innate Pharma 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33 Is CALC or IPHA more profitable? Innate Pharma's return on equity of 0.00% beat CalciMedica's return on equity.Company Net Margins Return on Equity Return on Assets CalciMedicaN/A -206.51% -103.81% Innate Pharma N/A N/A N/A Does the media favor CALC or IPHA? In the previous week, CalciMedica and CalciMedica both had 3 articles in the media. Innate Pharma's average media sentiment score of 1.27 beat CalciMedica's score of 0.63 indicating that Innate Pharma is being referred to more favorably in the news media. Company Overall Sentiment CalciMedica Positive Innate Pharma Positive Which has more risk and volatility, CALC or IPHA? CalciMedica has a beta of 1.32, meaning that its stock price is 32% more volatile than the S&P 500. Comparatively, Innate Pharma has a beta of 0.22, meaning that its stock price is 78% less volatile than the S&P 500. SummaryInnate Pharma beats CalciMedica on 9 of the 12 factors compared between the two stocks. Get CalciMedica News Delivered to You Automatically Sign up to receive the latest news and ratings for CALC and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CALC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CALC vs. The Competition Export to ExcelMetricCalciMedicaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$47.92M$3.20B$5.85B$10.14BDividend YieldN/A2.30%5.68%4.60%P/E Ratio-1.9821.4375.3425.98Price / SalesN/A430.69514.97181.19Price / CashN/A46.6837.5660.44Price / Book2.969.6112.156.29Net Income-$13.70M-$53.29M$3.29B$271.07M7 Day Performance2.92%0.13%0.75%3.87%1 Month Performance33.76%5.61%4.82%4.88%1 Year Performance-18.82%10.49%60.59%26.12% CalciMedica Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CALCCalciMedica2.4781 of 5 stars$3.17-7.6%$16.00+404.7%-23.8%$47.92MN/A-1.9830Short Interest ↑IPHAInnate Pharma3.0163 of 5 stars$2.03-0.5%$11.00+441.9%-12.3%$187.13M$21.77M0.00220Positive NewsUpcoming EarningsNLTXNeoleukin TherapeuticsN/A$19.45-2.5%N/A-50.2%$182.79MN/A-6.2590High Trading VolumeBDTXBlack Diamond Therapeutics3.4466 of 5 stars$3.17+3.8%$11.67+268.6%-44.4%$180.78MN/A13.8090Positive NewsBIOABioAge Labs0.2005 of 5 stars$5.00-1.8%N/AN/A$179.25M$3.86M0.00N/AFTLFFitLife Brands4.3344 of 5 stars$19.00-0.7%$23.00+21.1%+5.0%$178.36M$64.47M22.6120Positive NewsCGTXCognition Therapeutics2.8095 of 5 stars$2.41+0.5%$2.83+17.5%+259.5%$178.29MN/A-3.6220Short Interest ↑MDWDMediWound1.6393 of 5 stars$16.34-2.4%$32.25+97.4%+1.3%$176.57M$19.86M-6.1980TILInstil Bio2.8538 of 5 stars$25.71-0.2%$119.00+362.9%-48.1%$174.75MN/A-2.00410Analyst ForecastInsider TradeTVGNTevogen Bio3.9081 of 5 stars$0.88+0.2%$10.00+1,035.1%+75.8%$172.71MN/A0.003Gap UpSXTCChina SXT Pharmaceuticals1.3055 of 5 stars$1.48-10.3%N/A-62.5%$172.31M$1.74M0.0090Positive NewsShort Interest ↓ Related Companies and Tools Related Companies Innate Pharma Alternatives Neoleukin Therapeutics Alternatives Black Diamond Therapeutics Alternatives BioAge Labs Alternatives FitLife Brands Alternatives Cognition Therapeutics Alternatives MediWound Alternatives Instil Bio Alternatives Tevogen Bio Alternatives China SXT Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CALC) was last updated on 9/13/2025 by MarketBeat.com Staff From Our PartnersWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredOctober 16 Changes the Microchip Game — and InvestingWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CalciMedica Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CalciMedica With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
